BACKGROUND: Osteopenia is common in the era of effective antiretroviral therapy (ART), yet the etiology is unclear. We evaluated the association of host factors, disease severity, and ART to changes in total body bone mineral density (total BMD) over time in HIV-infected men (n = 283) and women (n = 96). METHODS: Total BMD was measured annually by whole-body dual-energy absorptiometry (DXA), and medical, dietary, and behavioral history was collected. The median time from first to last DXA was 2.5 years (range 0.9-6.8 years). Using a repeated measures regression model, we identified variables independently associated with percent change in total BMD between consecutive DXA exams (n = 799 intervals), adjusted for age, race, sex, menopause, and smoking. We estimated percent change in total BMD over an average interval (1 year) standardized for representative levels of each determinant in males, premenopausal women, and postmenopausal women. RESULTS: Median baseline age, CD4, and viral load were 42 years, 364 cells per cubic millimeter, and 2.7 log10 copies per milliliter, respectively. The estimated change in total BMD for those not on ART was -0.37% per year [95% confidence interval (CI) -0.76 to -0.02] for men, -0.08% per year (95% CI -0.49 to 0.33) for premenopausal women, and -1.07% per year (95% CI -1.86 to -0.28) for postmenopausal women. Greater loss of total BMD was associated with lower albumin, lower body mass index, prednisone/hydrocortisone use, tenofovir use, and longer duration of didanosine. Strength training and long duration of d4T and saquinavir prevented or mitigated bone loss. For those on ART for 3 years (not including the above agents), the rate of loss was -0.57% per year (95% CI -1.00 to -0.14) for men, -0.28% (95% CI -0.71 to 0.15) for premenopausal women, and -1.27% (95% CI -2.07 to -0.47) for postmenopausal women. Postmenopausal women had greater loss than premenopausal women and men. CONCLUSIONS: Low body weight, low albumin, catabolic steroid use, and menopause may accelerate bone loss, and strength training may be protective. Tenofovir and didanosine may also have a deleterious effect on BMD.
BACKGROUND:Osteopenia is common in the era of effective antiretroviral therapy (ART), yet the etiology is unclear. We evaluated the association of host factors, disease severity, and ART to changes in total body bone mineral density (total BMD) over time in HIV-infectedmen (n = 283) and women (n = 96). METHODS: Total BMD was measured annually by whole-body dual-energy absorptiometry (DXA), and medical, dietary, and behavioral history was collected. The median time from first to last DXA was 2.5 years (range 0.9-6.8 years). Using a repeated measures regression model, we identified variables independently associated with percent change in total BMD between consecutive DXA exams (n = 799 intervals), adjusted for age, race, sex, menopause, and smoking. We estimated percent change in total BMD over an average interval (1 year) standardized for representative levels of each determinant in males, premenopausal women, and postmenopausal women. RESULTS: Median baseline age, CD4, and viral load were 42 years, 364 cells per cubic millimeter, and 2.7 log10 copies per milliliter, respectively. The estimated change in total BMD for those not on ART was -0.37% per year [95% confidence interval (CI) -0.76 to -0.02] for men, -0.08% per year (95% CI -0.49 to 0.33) for premenopausal women, and -1.07% per year (95% CI -1.86 to -0.28) for postmenopausal women. Greater loss of total BMD was associated with lower albumin, lower body mass index, prednisone/hydrocortisone use, tenofovir use, and longer duration of didanosine. Strength training and long duration of d4T and saquinavir prevented or mitigated bone loss. For those on ART for 3 years (not including the above agents), the rate of loss was -0.57% per year (95% CI -1.00 to -0.14) for men, -0.28% (95% CI -0.71 to 0.15) for premenopausal women, and -1.27% (95% CI -2.07 to -0.47) for postmenopausal women. Postmenopausal women had greater loss than premenopausal women and men. CONCLUSIONS: Low body weight, low albumin, catabolic steroid use, and menopause may accelerate bone loss, and strength training may be protective. Tenofovir and didanosine may also have a deleterious effect on BMD.
Authors: A L Moore; A Vashisht; C A Sabin; A Mocroft; S Madge; A N Phillips; J W Studd; M A Johnson Journal: AIDS Date: 2001-09-07 Impact factor: 4.177
Authors: G Tsekes; G Chrysos; G Douskas; D Paraskeva; N Mangafas; D Giannakopoulos; M Papanikolaou; E Georgiou; M C Lazanas Journal: HIV Med Date: 2002-04 Impact factor: 3.180
Authors: T V Nguyen; L M Maynard; B Towne; A F Roche; W Wisemandle; J Li; S S Guo; W C Chumlea; R M Siervogel Journal: J Clin Densitom Date: 2001 Impact factor: 2.963
Authors: Philip M Grant; Douglas Kitch; Grace A McComsey; Michael P Dube; Richard Haubrich; Jeannie Huang; Sharon Riddler; Pablo Tebas; Andrew R Zolopa; Ann C Collier; Todd T Brown Journal: Clin Infect Dis Date: 2013-08-13 Impact factor: 9.079
Authors: Kathryn E Childs; Sarah L Fishman; Catherine Constable; Julio A Gutierrez; Christina M Wyatt; Douglas T Dieterich; Michael P Mullen; Andrea D Branch Journal: AIDS Res Hum Retroviruses Date: 2010-08 Impact factor: 2.205
Authors: James M McMahon; Julie E Myers; Ann E Kurth; Stephanie E Cohen; Sharon B Mannheimer; Janie Simmons; Enrique R Pouget; Nicole Trabold; Jessica E Haberer Journal: AIDS Patient Care STDS Date: 2014-07-21 Impact factor: 5.078
Authors: Robert C Kalayjian; Jeffrey M Albert; Serge Cremers; Samir K Gupta; Grace A McComsey; Karin L Klingman; Carl J Fichtenbaum; Todd T Brown; Babafemi O Taiwo Journal: AIDS Date: 2018-11-13 Impact factor: 4.177
Authors: Kristine M Erlandson; Jordan E Lake; Myung Sim; Julian Falutz; Carla M Prado; Ana Rita Domingues da Silva; Todd T Brown; Giovanni Guaraldi Journal: J Acquir Immune Defic Syndr Date: 2018-03-01 Impact factor: 3.731